AstraZeneca Hits Sandoz With Seroquel Patent Suit

Law360, New York (April 10, 2007, 12:00 AM EDT) -- AstraZeneca Pharmaceuticals LP has filed suit against the generics arm of Novartis AG in an attempt to stave off competition in the multibillion-dollar market for schizophrenia and bipolar mania treatment Seroquel.

The suit was filed Friday in New Jersey on behalf of AstraZeneca Pharmaceuticals LP and AstraZeneca UK Limited against Sandoz Inc.

The suit centers on U.S. Patent Number 4,879,288—entitled “novel dibenzothiazepine antipsychotic” and owned by AstraZeneca. The ‘288 patent covers quetiapine fumarate, the active ingredient in Seroquel.

The ‘288 patent had been slated to expire...
To view the full article, register now.